CYP51 as drug targets for fungi and protozoan parasites: past, present and future

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Parasitology

• Publication date

  2018-04-12

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1017/S0031182018000562PMID 29642960PMCID PMC6185833
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Posaconazole

  2020cited by this paper
• Invasive Candidiasis.

  2019cited by this paper
• Chagas disease.

  2018cited by this paper
• Isavuconazole: is there a need for a new antifungal?

  2017cited by this paper
• Variant surface glycoprotein density defines an immune evasion threshold for African trypanosomes undergoing antigenic variation

  2017cited by this paper
• Characterisation of sterol biosynthesis and validation of 14α-demethylase as a drug target in Acanthamoeba

  2017cited by this paper
• Antitrypanosomal Activity of Sterol 14α-Demethylase (CYP51) Inhibitors VNI and VFV in the Swiss Mouse Models of Chagas Disease Induced by the Trypanosoma cruzi Y Strain

  2017cited by this paper
• P450 inhibitor ketoconazole increased the intratumor drug levels and antitumor activity of fenretinide in human neuroblastoma xenograft models

  2017cited by this paper
• Benznidazole and Posaconazole in Eliminating Parasites in Asymptomatic T. Cruzi Carriers: The STOP-CHAGAS Trial.

  2017cited by this paper
• Crystal Structure of the New Investigational Drug Candidate VT-1598 in Complex with Aspergillus fumigatus Sterol 14α-Demethylase Provides Insights into Its Broad-Spectrum Antifungal Activity

  2017cited by this paper
• A Review of the Clinical Pharmacokinetics and Pharmacodynamics of Isavuconazole

  2017cited by this paper
• Antileishmanial Efficacy and Pharmacokinetics of DB766-Azole Combinations

  2017cited by this paper
• Structural analyses of Candida albicans sterol 14α-demethylase complexed with azole drugs address the molecular basis of azole-mediated inhibition of fungal sterol biosynthesis

  2017cited by this paper
• Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America.

  2016cited by this paper
• The development of fluconazole resistance in Candida albicans – an example of microevolution of a fungal pathogen

  2016cited by this paper
• Ligand tunnels in T. brucei and human CYP51: Insights for parasite-specific drug design.

  2016cited by this paper
• Executive Summary: Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America.

  2016cited by this paper
• Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial.

  2016cited by this paper
• Fungal CYP51 Inhibitors VT-1161 and VT-1129 Exhibit Strong In Vitro Activity against Candida glabrata and C. krusei Isolates Clinically Resistant to Azole and Echinocandin Antifungal Compounds

  2016cited by this paper
• Human sterol 14α-demethylase as a target for anticancer chemotherapy: towards structure-aided drug design1

  2016cited by this paper
• Allergic Bronchopulmonary Aspergillosis

  2016cited by this paper
• Safety, clinical effectiveness and trough plasma concentrations of intravenous posaconazole in patients with haematological malignancies and/or undergoing allogeneic haematopoietic stem cell transplantation: off-trial experience.

  2016cited by this paper
• Trypanosoma brucei CYP51: Essentiality and Targeting Therapy in an Experimental Model

  2016cited by this paper
• Posaconazole: Use in the Prophylaxis and Treatment of Fungal Infections

  2015influential reference
• Fungal infections in the ICU: advances in treatment and diagnosis

  2015cited by this paper
• Azole Antifungal Agents To Treat the Human Pathogens Acanthamoeba castellanii and Acanthamoeba polyphaga through Inhibition of Sterol 14α-Demethylase (CYP51)

  2015cited by this paper
• VFV as a New Effective CYP51 Structure-Derived Drug Candidate for Chagas Disease and Visceral Leishmaniasis.

  2015cited by this paper
• Chagas' Disease.

  2015cited by this paper
• Discovery of an ergosterol-signaling factor that regulates Trypanosoma brucei growth[S]

  2015cited by this paper
• The use of posaconazole against Chagas disease

  2015cited by this paper
• Clinical Candidate VT-1161's Antiparasitic Effect In Vitro, Activity in a Murine Model of Chagas Disease, and Structural Characterization in Complex with the Target Enzyme CYP51 from Trypanosoma cruzi

  2015cited by this paper
• Isavuconazole

  2015cited by this paper
• How to bolster the antifungal pipeline

  2015cited by this paper
• Structure-Functional Characterization of Cytochrome P450 Sterol 14α-Demethylase (CYP51B) from Aspergillus fumigatus and Molecular Basis for the Development of Antifungal Drugs*

  2015cited by this paper
• Isavuconazole: Pharmacology, Pharmacodynamics, and Current Clinical Experience with a New Triazole Antifungal Agent

  2015cited by this paper
• Therapeutic Drug Monitoring of Voriconazole in the Management of Invasive Fungal Infections: A Critical Review

  2015cited by this paper
• Tissue Penetration of Antifungal Agents

  2014cited by this paper
• Randomized trial of posaconazole and benznidazole for chronic Chagas' disease.

  2014cited by this paper
• Intermediate cutaneous leishmaniasis caused by Leishmania (Viannia) braziliensis successfully treated with fluconazole

  2014cited by this paper
• Structural Basis for Rational Design of Inhibitors Targeting Trypanosoma cruzi Sterol 14α-Demethylase: Two Regions of the Enzyme Molecule Potentiate Its Inhibition

  2014cited by this paper
• Sequence variation in CYP51A from the Y strain of Trypanosoma cruzi alters its sensitivity to inhibition

  2014cited by this paper
• [Infectious diseases].

  2014cited by this paper
• Wild and synanthropic reservoirs of Leishmania species in the Americas

  2014cited by this paper
• Treatment of Chagas' disease with itraconazole: electrocardiographic and parasitological conditions after 20 years of follow-up.

  2013cited by this paper
• VNI cures acute and chronic experimental Chagas disease.

  2013cited by this paper
• Invasive fungal infections.

  2013cited by this paper
• Efficacy of voriconazole in a murine model of acute Trypanosoma cruzi infection.

  2013cited by this paper
• Design or screening of drugs for the treatment of Chagas disease: what shows the most promise?

  2013cited by this paper
• Efinaconazole: First Global Approval

  2013cited by this paper
• Antitrypanosomal lead discovery: identification of a ligand-efficient inhibitor of Trypanosoma cruzi CYP51 and parasite growth.

  2013cited by this paper
• Complexes of Trypanosoma cruzi Sterol 14α-Demethylase (CYP51) with Two Pyridine-based Drug Candidates for Chagas Disease

  2013cited by this paper
• Optimizing antifungal choice and administration

  2013cited by this paper
• Pharmacological Characterization, Structural Studies, and In Vivo Activities of Anti-Chagas Disease Lead Compounds Derived from Tipifarnib

  2012cited by this paper
• Structural complex of sterol 14α-demethylase (CYP51) with 14α-methylenecyclopropyl-Δ7-24, 25-dihydrolanosterol[S]

  2012cited by this paper
• Clotrimazole: A Review of its Antifungal Activity and Therapeutic Efficacy

  2012cited by this paper
• Posaconazole

  2012cited by this paper
• Treatment of granulomatous amoebic encephalitis with voriconazole and miltefosine in an immunocompetent soldier.

  2012cited by this paper
• Recent Developments in Sterol 14-demethylase Inhibitors for Chagas Disease.

  2012cited by this paper
• Pathogenic free-living amoebae: epidemiology and clinical review.

  2012cited by this paper
• CYP51 structures and structure-based development of novel, pathogen-specific inhibitory scaffolds.

  2012cited by this paper
• Successful monitoring and treatment of intraocular dissemination of acanthamoeba.

  2012cited by this paper
• Antifungal Agents Used in Systemic Mycoses

  2012cited by this paper
• Successful Treatment of Brainstem Blastomycosis with Fluconazole

  2012cited by this paper
• Ketoconazole: A Review of its Therapeutic Efficacy in Superficial and Systemic Fungal Infections

  2012cited by this paper
• Statins personalized.

  2012cited by this paper
• Invasive Fungal Infections

  2012cited by this paper
• Miconazole: A Review of its Antifungal Activity and Therapeutic Efficacy

  2012cited by this paper
• Substrate Preferences and Catalytic Parameters Determined by Structural Characteristics of Sterol 14α-Demethylase (CYP51) from Leishmania infantum*

  2011cited by this paper
• Biosynthesis of Cholesterol and Other Sterols

  2011cited by this paper
• High-dose oral fluconazole therapy effective for cutaneous leishmaniasis due to Leishmania (Vianna) braziliensis.

  2011cited by this paper
• Trypanosoma cruzi and Chagas' Disease in the United States

  2011cited by this paper
• Triazole Antifungal Agents in Invasive Fungal Infections

  2011influential reference
• Successful Treatment of Old World Cutaneous Leishmaniasis Caused by Leishmania infantum with Posaconazole

  2011cited by this paper
• Structural basis for conservation in the CYP51 family.

  2011cited by this paper
• Transactions of the Royal Society of Tropical Medicine and Hygiene

  2011cited by this paper
• Biosynthesis of cholesterol and other sterols.

  2011cited by this paper
• Infectious diseases. Drug developers finally take aim at a neglected disease.

  2011cited by this paper
• Structural Insights into Inhibition of Sterol 14α-Demethylase in the Human Pathogen Trypanosoma cruzi*

  2010cited by this paper
• Impact of cyp51A Mutations on the Pharmacokinetic and Pharmacodynamic Properties of Voriconazole in a Murine Model of Disseminated Aspergillosis

  2010cited by this paper
• Successful treatment with posaconazole of a patient with chronic Chagas disease and systemic lupus erythematosus.

  2010cited by this paper
• Conazoles

  2010cited by this paper
• Venous thromboembolism in cancer patients: ESMO Clinical Practice Guidelines for the management.

  2010cited by this paper
• Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america.

  2010cited by this paper
• Treatment with voriconazole in 3 eyes with resistant Acanthamoeba keratitis.

  2010cited by this paper
• Successful Treatment of Chronic Stromal Acanthamoeba Keratitis With Oral Voriconazole Monotherapy

  2010cited by this paper
• Intracellular Concentrations of Posaconazole in Different Compartments of Peripheral Blood

  2010cited by this paper
• Pharmacokinetic/Pharmacodynamic Profile of Posaconazole

  2010cited by this paper
• Voriconazole therapeutic drug monitoring: focus on safety

  2010cited by this paper
• Indomethacin amides as a novel molecular scaffold for targeting Trypanosoma cruzi sterol 14alpha-demethylase.

  2009cited by this paper
• A new consensus for Trypanosoma cruzi intraspecific nomenclature: second revision meeting recommends TcI to TcVI.

  2009cited by this paper
• Murine Model of a Disseminated Infection by the Novel Fungus Fonsecaea monophora and Successful Treatment with Posaconazole

  2009cited by this paper
• Pharmacokinetics and Pharmacodynamics of a Novel Triazole, Isavuconazole: Mathematical Modeling, Importance of Tissue Concentrations, and Impact of Immune Status on Antifungal Effect

  2009cited by this paper
• Correlation of In Vitro Activity, Serum Levels, and In Vivo Efficacy of Posaconazole against Rhizopus microsporus in a Murine Disseminated Infection

  2009cited by this paper
• Crystal Structures of Trypanosoma brucei Sterol 14α-Demethylase and Implications for Selective Treatment of Human Infections*♦

  2009cited by this paper
• Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents.

  2009cited by this paper
• CYP51: A Major Drug Target in the Cytochrome P450 Superfamily

  2008cited by this paper
• Posaconazole (Noxafil, SCH 56592), a new azole antifungal drug, was a discovery based on the isolation and mass spectral characterization of a circulating metabolite of an earlier lead (SCH 51048).

  2008cited by this paper
• A Short History of Fungicides.

  2008cited by this paper
• Therapeutic Drug Monitoring of Voriconazole

  2008cited by this paper
• A case of successful treatment of cutaneous Acanthamoeba infection in a lung transplant recipient

  2007cited by this paper

• The Ultimate Micro-Exon: A Single Nucleotide Exon Is Required to Assemble Cytochrome P450 CYP621A Orthologs from Fusarium Species.

  2026cites this paper
• The Significance of Mono‐ and Dual‐Effective Agents in the Development of New Antifungal Strategies

  2025cites this paper
• Thiosemicarbazones and thiazoles antifungal activity against Sporothrix and first Sporothrix mexicana from human sporotrichosis in Brazil.

  2025cites this paper
• Synthesis and Biological Evaluation of Itraconazole Derivatives: Design in an Old Scaffold.

  2025cites this paper
• Structure-based design of a novel series of cholesterol 24-hydroxylase (CH24H) inhibitors bearing 1,3-oxazole as a heme-iron binding group.

  2025cites this paper
• Unique Structural Features Relate to Evolutionary Adaptation of Cytochrome P450 in the Abyssal Zone

  2025cites this paper
• Progress and Prospects of Triazoles in Advanced Therapies for Parasitic Diseases

  2025cites this paper
• Re-sensitization of antimony-resistant Leishmania by highly potent SbV-porphyrin through the involvement of ERG6-coding gene.

  2025cites this paper
• Exploring P450 superfamily diversity with P450Atlas ‐ Online tool for automated subfamily assignment

  2025cites this paper
• Exploring a series of multifunctional Mn(I) tricarbonyls as prospective agents against trypanosomatid parasites: a comparative study with the Re(I) analogues.

  2025cites this paper
• Drug screening and development cascade for Chagas disease: an update of in vitro and in vivo experimental models

  2024cites this paper
• Design, Synthesis, and Activity Evaluation of Novel Benzazole Bifunctional Antifungal Inhibitors with an LDH Carrier.

  2024cites this paper
• Construction and Activity Evaluation of Novel Bifunctional Inhibitors and a COF Carrier Based on a Fungal Infection Microenvironment.

  2024cites this paper
• Structure–Function Analysis of the Essential Mycobacterium tuberculosis P450 Drug Target, CYP121A1

  2024cites this paper
• Identification of Potent and Selective Inhibitors of Acanthamoeba: Structural Insights into Sterol 14α-Demethylase as a Key Drug Target

  2024cites this paper
• Metalloenzyme Inhibitors against Zoonotic Infections: Focus on Leishmania and Schistosoma.

  2024cites this paper
• Increasing the tolerance of Trichoderma harzianum T-22 to DMI fungicides enables the combined utilization of biological and chemical control strategies against plant diseases

  2024cites this paper
• Unleashing the potential of vanillic acid: A new twist on nature's recipe to fight inflammation and circumvent azole-resistant fungal infections.

  2024cites this paper
• Antifungal and Antiparasitic Activities of Metallocene-Containing Fluconazole Derivatives.

  2024cites this paper
• Druggable Sterol Metabolizing Enzymes in Infectious Diseases: Cell Targets to Therapeutic Leads

  2024cites this paper
• Advancing Treatment for Leishmaniasis: From Overcoming Challenges to Embracing Therapeutic Innovations.

  2024cites this paper
• Unique structural features in a deep-sea CYP51 relate to high pressure adaptation

  2024cites this paper
• In Silico Study of FDA-Approved Drugs on Leishmania infantum CYP51, a Drug Repositioning Approach in Visceral Leishmaniasis

  2024cites this paper
• Molecular modelling and experimental validation identified a new therapeutic inhibitor of toxoplasmosis

  2024cites this paper
• 1,2,4-Oxadiazole Derivatives: Physicochemical Properties, Antileishmanial Potential, Docking and Molecular Dynamic Simulations of Leishmania infantum Target Proteins

  2024cites this paper
• In vitro and in silico evaluation of the anti-leishmania activity of synthetic chalcones

  2024cites this paper
• Updates on Mechanisms of Cytochrome P450 Catalysis of Complex Steroid Oxidations

  2024cites this paper
• Chiral Fluorescent Antifungal Azole Probes Detect Resistance, Uptake Dynamics, and Subcellular Distribution in Candida Species

  2024cites this paper
• Comparative Genome-Wide Analysis Underscores the Rapid Expansion of Cytochrome P450s for Secondary Metabolism in the Mycoparasite Pezizomycetes

  2024cites this paper
• Multifunctional organometallic compounds for the treatment of Chagas disease: Re(I) tricarbonyl compounds with two different bioactive ligands.

  2023cites this paper
• Structure–Function Analysis of the Biotechnologically Important Cytochrome P450 107 (CYP107) Enzyme Family

  2023cites this paper
• Genome-Wide Analysis of the Cytochrome P450 Monooxygenases in the Lichenized Fungi of the Class Lecanoromycetes

  2023cites this paper
• Cytochrome P450 Enzymes as Drug Targets in Human Disease

  2023cites this paper
• Construction and Evaluation of Novel Dual-function Antifungal Inhibitors and Covalent Organic Framework Carriers Based on the Infection Microenvironment.

  2023cites this paper
• Design, Synthesis, and Activity Evaluation of Novel Dual-Target Inhibitors with Antifungal and Immunoregulatory Properties.

  2023cites this paper
• Pezizomycetes Genomes Reveal Diverse P450 Complements Characteristic of Saprotrophic and Ectomycorrhizal Lifestyles

  2023cites this paper
• Processive kinetics in the three-step lanosterol 14α-demethylation reaction catalyzed by human cytochrome P450 51A1

  2023cites this paper
• Evolution of Cytochrome P450 Enzymes and Their Redox Partners in Archaea

  2023cites this paper
• Selene-Ethylenelacticamides and N-Aryl-Propanamides as Broad-Spectrum Leishmanicidal Agents

  2023cites this paper
• Sterol-Sensing Domain (SSD)-Containing Proteins in Sterol Auxotrophic Phytophthora capsici Mediate Sterol Signaling and Play a Role in Asexual Reproduction and Pathogenicity

  2023cites this paper
• Examination of multiple Trypanosoma cruzi targets in a new drug discovery approach for Chagas disease.

  2022cites this paper
• Computational investigation of the alkaloids of Pilocarpus microphyllus species as phytopharmaceuticals for the inhibition of sterol 14α-demethylase protease of Trypanosoma cruzi

  2022influential citation
• Perspectives for a new drug candidate for Chagas disease therapy

  2022cites this paper
• An Unprecedented Number of Cytochrome P450s Are Involved in Secondary Metabolism in Salinispora Species

  2022cites this paper
• Endogenous Sterol Synthesis Is Dispensable for Trypanosoma cruzi Epimastigote Growth but Not Stress Tolerance

  2022cites this paper
• Functional Analysis of the C-5 Sterol Desaturase PcErg3 in the Sterol Auxotrophic Oomycete Pathogen Phytophthora capsici

  2022cites this paper
• Synthesis, Design, and Structure‐Activity Relationship of a Benzenesulfonylpiperazine Series against Trypanosoma cruzi

  2022cites this paper
• Aromatic or Hetero-aromatic Directly Attached Tri and Tetrasubstituted Methanes: New Chemical Entities as Anti-infectives.

  2022cites this paper
• The Anti-Fungal Activity of Nitropropenyl Benzodioxole (NPBD), a Redox-Thiol Oxidant and Tyrosine Phosphatase Inhibitor

  2022cites this paper
• Fexinidazole interferes with the growth and structural organization of Trypanosoma cruzi

  2022cites this paper
• Chemical Composition and In Vitro and In Silico Antileishmanial Evaluation of the Essential Oil from Croton linearis Jacq. Stems

  2022cites this paper
• Saprophytic to Pathogenic Mycobacteria: Loss of Cytochrome P450s Vis a Vis Their Prominent Involvement in Natural Metabolite Biosynthesis

  2022cites this paper
• Biophysical techniques for distinguishing ligand binding modes in cytochrome P450 monooxygenases

  2021cites this paper
• Relaxed Substrate Requirements of Sterol 14α-Demethylase from Naegleria fowleri Are Accompanied by Resistance to Inhibition.

  2021cites this paper
• A chemical biology approach reveals a dependency of glioblastoma on biotin distribution

  2021cites this paper
• Glucosyl‐1,2,3‐triazoles derived from eugenol and analogues: Synthesis, anti‐Candida activity, and molecular modeling studies in CYP‐51

  2021cites this paper
• Higher oral efficacy of ravuconazole in self-nanoemulsifying systems in shorter treatment in experimental chagas disease.

  2021cites this paper
• In Silico Structural Modeling and Analysis of Interactions of Tremellomycetes Cytochrome P450 Monooxygenases CYP51s with Substrates and Azoles

  2021influential citation
• Discovery of 1,2,3-selenadiazole analogues as antifungal agents using a scaffold hopping approach.

  2021cites this paper
• Drug Discovery and Development for Kinetoplastid Diseases

  2021cites this paper
• The mysterious route of sterols in oomycetes

  2021cites this paper
• Ancient Bacterial Class Alphaproteobacteria Cytochrome P450 Monooxygenases Can Be Found in Other Bacterial Species

  2021cites this paper
• Synthesis of triazole-containing ciprofloxacin conjugate and its in silico test as a cytochrome P450 ligand

  2021cites this paper
• Phytosterol Profiles, Genomes and Enzymes – An Overview

  2021cites this paper
• In silico Discovery of a New Potent Inhibitor for Sterol 14-alpha Demethylase as a Promising Antifungal Drug against Aspergillus fumigatus Infection

  2021cites this paper
• In Silico Analysis of P450s and Their Role in Secondary Metabolism in the Bacterial Class Gammaproteobacteria

  2021influential citation
• Lead optimization generates selenium-containing miconazole CYP51 inhibitors with improved pharmacological profile for the treatment of fungal infections.

  2021cites this paper
• Analysis of the Contribution of cyp51 Genes to Azole Resistance in Aspergillus Section Nigri with the CRISPR-Cas9 Technique

  2021cites this paper
• Development of an itraconazole resistance gene as a dominant selectable marker for transformation in Aspergillus oryzae and Aspergillus luchuensis.

  2021cites this paper
• Effect of Itraconazole-Ezetimibe-Miltefosine Ternary Therapy in Murine Visceral Leishmaniasis

  2021cites this paper
• To Be, or Not to Be, an Inhibitor: A Comparison of Azole Interactions with and Oxidation by a Cytochrome P450 Enzyme.

  2021cites this paper
• Synthesis and Antileishmanial Evaluation of Arylimidamide-Azole Hybrids Containing a Phenoxyalkyl Linker.

  2021cites this paper
• Roles for Structural Biology in the Discovery of Drugs and Agrochemicals Targeting Sterol 14α-Demethylases

  2021influential citation
• Emerging agents for the treatment of Chagas disease: what is in the preclinical and clinical development pipeline?

  2020cites this paper
• OP-MOLB200261 1..16

  2020cites this paper
• Transcriptome sequencing revealed the inhibitory mechanism of ketoconazole on clinical Microsporum canis

  2020cites this paper
• Nanoemulsified Butenafine for Enhanced Performance against Experimental Cutaneous Leishmaniasis

  2020cites this paper
• Pyridylethanol(phenylethyl)amines are non-azole, highly selective Candida albicans sterol 14α-demethylase inhibitors.

  2020cites this paper
• Protothecosis in Dogs and Cats—New Research Directions

  2020cites this paper
• Novel naphthylamide derivatives as dual-target antifungal inhibitors: Design, synthesis and biological evaluation.

  2020cites this paper
• Etiologic Treatment of Chagas Disease: Old Drugs, New Insights, Challenges, and Perspectives

  2020cites this paper
• Pharmacology Profile of Recently Developed Multi‐Functional Azoles; SAR‐Based Predictive Structural Modification

  2020cites this paper
• Concerning P450 Evolution: Structural Analyses Support Bacterial Origin of Sterol 14α-Demethylases

  2020cites this paper
• Multi-level analysis of exposure to triazole fungicides through treated seed ingestion in the red-legged partridge.

  2020cites this paper
• Molecular Dynamics Investigations of Binding Mechanism for Triazoles Inhibitors to CYP51

  2020cites this paper
• Challenges in Chagas Disease Drug Development

  2020cites this paper
• A requirement for an active proton delivery network supports a compound I-mediated C–C bond cleavage in CYP51 catalysis

  2020cites this paper
• Effect of itraconazole on Staphylococcus aureus biofilm and extracellular vesicles formation.

  2020cites this paper
• Amlodipine Increases the Therapeutic Potential of Ravuconazole upon Trypanosoma cruzi Infection

  2020cites this paper
• Design, synthesis, and biological evaluation of novel miconazole analogues containing selenium as potent antifungal agents.

  2020cites this paper
• Thiazolidinone-Related Heterocyclic Compounds as Potential Antitrypanosomal Agents

  2020cites this paper
• Inhibition of Phytosterol Biosynthesis by Azasterols

  2020cites this paper
• Biophysical techniques to distinguish ligand binding modes in cytochrome P450 monooxygenases.

  2020cites this paper
• Hits and Lead Discovery in the Identification of New Drugs against the Trypanosomatidic Infections

  2019cites this paper
• Advances in preclinical approaches to Chagas disease drug discovery

  2019influential citation
• Synthesis, PASS predication, in vitro antimicrobial evaluation and pharmacokinetic study of novel n-octyl glucopyranoside esters.

  2019cites this paper
• Validation of human sterol 14α-demethylase (CYP51) druggability: structure-guided design, synthesis and evaluation of stoichiometric, functionally irreversible inhibitors.

  2019cites this paper
• Design, Synthesis, and Biological Evaluation of New 1-(Aryl-1 H-pyrrolyl)(phenyl)methyl-1 H-imidazole Derivatives as Antiprotozoal Agents.

  2019cites this paper
• Successful Aspects of the Coadministration of Sterol 14α-Demethylase Inhibitor VFV and Benznidazole in Experimental Mouse Models of Chagas Disease Caused by the Drug-Resistant Strain of Trypanosoma cruzi.

  2019cites this paper
• Parasite, Compartments, and Molecules: Trick versus Treatment on Chagas Disease

  2019influential citation